Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Health Catalyst ( (HCAT) ) has shared an update.
On February 12, 2026, Health Catalyst appointed Ben Albert, formerly its president and chief operating officer and previously CEO of acquired patient-engagement firm Upfront Healthcare Services, as chief executive officer and a Class III director, while accelerating the planned retirement of long-time CEO Dan Burton. Albert’s compensation package includes a $600,000 base salary and extensive time- and performance-based restricted stock awards, underscoring the board’s intent to align his incentives with long-term financial and operational performance while he drives cost-efficiency, improved execution, and a return to growth.
Burton stepped down as CEO and director effective February 12, 2026, but will remain as a strategic adviser, with the company expecting to formalize his transition in a separate agreement, and the board emphasized that his departure stemmed from succession timing rather than strategic disagreements. The leadership handover follows Albert’s internal restructuring efforts since September 2025 to streamline the organization and concentrate resources on high-return priorities, signaling a push to sharpen focus on margin improvement and more disciplined operations.
The company also enacted sweeping board changes, with directors Dawn Smith and Duncan Gallagher resigning effective February 17, 2026 and John Kane set to depart April 1, 2026, alongside the previously announced exit of director Matt Kolb at the 2026 annual meeting. In recognition of their service, the board accelerated vesting of restricted stock units and, in some cases, granted additional RSUs or full quarterly cash-equivalent retainers, indicating an orderly, non-contentious refresh of governance rather than activist-driven pressure.
As part of the shake-up, Justin Spencer was named independent chair of the board on February 12, 2026, and committee leadership was reconfigured, with Kane remaining as audit chair until his exit, Julie Larson-Green continuing to lead compensation, and Matt Arens assuming the chair of nominating and corporate governance. The board size was briefly increased to ten to accommodate Albert’s appointment and then scheduled for staged reductions to five directors by the time of the 2026 annual meeting, a move that is likely to tighten board oversight and may lower governance costs while concentrating authority among a smaller group of directors.
The most recent analyst rating on (HCAT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Health Catalyst stock, see the HCAT Stock Forecast page.
Spark’s Take on HCAT Stock
According to Spark, TipRanks’ AI Analyst, HCAT is a Neutral.
Health Catalyst’s overall stock score is primarily impacted by its financial performance challenges, including consistent losses and negative profitability metrics. While the earnings call provided some positive insights, such as exceeding financial guidance and strategic operational successes, the technical analysis and valuation remain weak. The recent corporate event of appointing a new President is a positive strategic move, but it does not outweigh the significant financial and valuation concerns.
To see Spark’s full report on HCAT stock, click here.
More about Health Catalyst
Health Catalyst, Inc., listed on Nasdaq as HCAT, is a healthcare data and analytics technology company providing cloud-based platforms, AI-enabled analytics tools, and related services to more than 1,100 organizations worldwide. Its Health Catalyst Ignite ecosystem and expert services are aimed at improving clinical, financial, and operational outcomes across hundreds of millions of patient records, positioning the firm as a key player in data-informed healthcare improvement and efficiency.
Backed by a multi-decade mission and a record of delivering billions of dollars in measurable results, Health Catalyst focuses on helping providers manage costs, enhance clinical quality, and strengthen consumer experience and loyalty. Its offerings target healthcare systems seeking standardized data, performance measurement, and actionable insight generation, reinforcing the company’s role as an enabler of value-based, outcomes-driven care.
Average Trading Volume: 688,572
Technical Sentiment Signal: Sell
Current Market Cap: $130.1M
Learn more about HCAT stock on TipRanks’ Stock Analysis page.